Nanosonics Limited · ASX:NAN
Nanosonics — Shareholder Meeting (November 2026)
43 slides from Nanosonics's shareholder meeting presentation, Nov 4, 2026
Slide 1: From a proven product, to a multi-platform leader
Dra v4 From a proven product, to a multi-pla orm leader. Annual General Meeting 2026 4 November 2026
Slide 2: A strongly independent Board with diverse skills
A strongly independent Board with diverse skills Steven Sargent BBus, Michael Kavanagh BSc, Marie McDonald BSc Larry Marshall BSc (Hons), FAICD, FTSE MBA (Advanced) (Hons), LLB (Hons), FAICD PhD, FAICD, FTSE, FAIP, Independent Non-executive CEO, President and Independent Non-executive Federation Fel
Slide 3: How to ask a question
How to ask a question • To ask a wri en question, select the Q & A icon. • Select the topic your question relates to from the drop-down list. • Type your question in the text box and press the send icon. • To ask a verbal question follow the instructions below the broadcast window. 3
Slide 4: How to vote
How to vote • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed 4
Slide 5: Steve Sargent, Non-executive Director and Chairman
Steve Sargent Non-executive Director and Chairman 5
Slide 6: Our focus is infection prevention, for life
Our focus is infection prevention, for life Our mission is to improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted by introducing innovative technologies that deliver improved standards of care. pa
Slide 7: Evolving infection prevention environment
Evolving infection prevention environment Leveraging its expertise in automation, medical reprocessing and digitisation, Nanosonics is leading the way to support healthcare providers to protect more patients. INFECTION PREVENTION DYNAMICS Technology advancements Safer for patients Driving solutions
Slide 8: Driving value creation
Driving value creation Nanosonics is entering a defining period of growth trophon business Creates opportunities model & performance for tomorrow Growing revenue & EBIT in constant currency Product growth & expansion Disciplined capital allocation CORIS Improving operating leverage commercialisation
Slide 9: Our commitment to sustainability
Our commitment to sustainability Caring for our customers and their patients, our partners, our people, the planet and the community. Five areas of focus reduction in Scope 1 and 2 emissions in FY26 80% reduction over the past 2 years 9
Slide 10: A strongly independent Board with diverse skills
A strongly independent Board with diverse skills Steven Sargent BBus, Michael Kavanagh BSc, Marie McDonald BSc Larry Marshall BSc (Hons), FAICD, FTSE MBA (Advanced) (Hons), LLB (Hons), FAICD PhD, FAICD, FTSE, FAIP, Independent Non-executive CEO, President and Independent Non-executive Federation Fel
Slide 11: Newly announced independent Non-executive Board member
Newly announced independent Non-executive Board member Julien Sauvagnargues Independent Non-executive Director Joining the Nanosonics Board on 1 December 2026 • Global MedTech executive • Two decades at Olympus • European and North American experience • Commercial, growth and operational experience
Slide 12: Building the future of automated infection prevention
Building the future of automated infection prevention Michael Kavanagh CEO, President and Managing Director 12
Slide 13: Led by an experienced team
Led by an experienced team Michael Kavanagh BSc, MBA Jason Burriss BCom, CA Kimberly Hill BSc Rod Lopez MBA, BEng (Hons), Ma hew Carbines LLB, Jodi Sampson MBA(Exec), (Advanced) GAICD Bcom CPHR, MAICD Chief Financial Officer Chief Marketing Officer & CEO, President and Managing Regional President, Asia
Slide 14: FY26: underlying growth, disciplined execution
FY26: underlying growth, disciplined execution A strong core business continued to fund investment in the next pla orm. $203.9m $211.5m 76.9% $21.6m $155.2m reported revenue revenue at CC gross margin EBIT at CC cash 3% growth 6% growth 77.6% at CC 21% growth no debt Core franchise strength Investme
Slide 15: Core trophon-only business profitability growing strongly
Core trophon-only business profitability growing strongly Generating cash and funding next pla orm growth. Sustained EBIT growth and high-quality cash conversion in the trophon-only business demonstrates durability and provides self- funded capacity for the next phase of growth. EBIT EBIT in CC $50.6
Slide 16: FY26 delivery positioned Nanosonics for its next phase
FY26 delivery positioned Nanosonics for its next phase Disciplined operational execution laid the foundations for the next phase of growth TROPHON CORIS OPERATIONS DIGITAL trophon3 and trophon2 Clearances across US consumables Connectivity and Plus launched; Australia, Europe and manufacturing trace
Slide 17: Nanosonics reaffirms FY27 guidance
Nanosonics reaffirms FY27 guidance Q1 FY27 performance is consistent with Nanosonics’ expectations. FY27 guidance at constant currency $220 million to $228 million, Revenue reflecting 8% to 12% growth on FY26. Gross Profit % 74%-76% Operational $156 million to $163 million, expenses reflecting 10% to 15%
Slide 18: From a single-platform company to a repeatable platform company
From a successful single-pla orm company to a repeatable pla orm company Repeat our capability selectively. Scale FUTURE CORIS. PLATFORMS Build CORIS from trophon. SECOND PLATFORM trophon PROVEN CORE 18
Slide 19: The opportunity is to automate what healthcare still performs manually
The opportunity is to automate what healthcare still performs manually Manual variability, fragmented records and workforce pressure create a broad class of problems to solve. Replace technique-dependent work with AUTOMATE automated workflows Deliver repeatable performance across STANDARDISE people a
Slide 20: The capability system to deliver our growth strategy
The capability R&D + engineering - Pla orm, product, so ware and consumables system to Clinical + medical – deliver our Need definition, evidence and adoption growth strategy Bioscience – biological models and testing Regulatory + quality - Global clearances and validated systems Integrated expertise
Slide 21: trophon still has a substantial runway for profitable growth
trophon still has a substantial runway for profitable growth The pla orm can compound through installed base, upgrades, utilisation and lifetime value. 39,230 8,000 $149.2m $50.6m installed base EPR upgrade opportunity recurring revenue trophon-only EBIT 6% FY26 growth remaining in North America FY26
Slide 22: Nanosonics CORIS System
Nanosonics CORIS® System. A new era in flexible endoscope reprocessing starts here.
Slide 23: A critical cleaning step, manual methods cannot reliably complete
A critical cleaning step, manual methods cannot reliably complete Cleaning is the critical first step in reprocessing flexible endoscopes, yet it remains manual, variable and unverified. The CORIS System automates it. THE PROBLEM THE SOLUTION Manual cleaning cannot reach every channel The CORIS System
Slide 24: Large CORIS recurring revenue opportunity
Large CORIS recurring revenue opportunity Capital, consumables and service compound as the installed base grows, leveraging the same annuity model as trophon. FY27 launch markets CAPITAL & ACCESSORIES UTILISATION UNITED KINGDOM & IRELAND 3-5X TROPHON ~10 capital price cycles per device per day >5M p
Slide 25: CORIS
nanosonics CORIS.
Slide 26: The CORIS System is delivering a consistently positive staff experience
The CORIS System is delivering a consistently positive staff experience UK CMR site feedback highlights strong workflow, usability and confidence in routine adoption OVERALL RESULT • Reduced hands-on manual cleaning Workflow & • Staff time can be redirected 4.65 / 5 capacity • Smoother, more predictable
Slide 27: UK & Ireland CORIS launch
UK & Ireland CORIS launch Manchester Science & Industry Museum 27
Slide 28: Medical & Scientific category
® Medical & Scientific category
Slide 29: A multi-platform leader in automated infection prevention
THE NANOSONICS VISION A multi-pla orm leader in automated infection prevention Build Scale Expand from CORIS trophon’s proven franchise and to redefine endoscope the por olio and geographic continuing growth reprocessing globally reach with discipline Building on trophon’s success to deliver the next
Slide 30: 30
30
Slide 31: Election of a Director, Ms Sarah Butler
Election of a Director, Ms Sarah Butler Sarah Butler FAICD Independent Non-executive Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Ms Sarah Butler, who was appointed as a Director by the Board on 20 January 2026 and retires as a Director in
Slide 32: Re-election of a Director, Dr Larry Marshall
Re-election of a Director, Dr Larry Marshall Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow Independent Non-executive Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr Larry Marshall, who retires as a Director by rotati
Slide 33: Re-election of a Director, Dr Tracey Batten
Re-election of a Director, Dr Tracey Ba en Tracey Ba en MBBS, MBA (Harvard), FAICD, MHA, FRACMA Independent Non-executive Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr Tracey Ba en, who retires as a Director by rotation in accordance wit
Slide 34: Adoption of Remuneration Report
Adoption of Remuneration Report To consider and, if thought fit, to pass the following advisory, non-binding resolution (in accordance with section 250R(3) of the Corporations Act) as an ordinary resolution: That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes,
Slide 35: Issue of 70,833 Service Rights to the CEO
Issue of 70,833 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2026 Short Term Incentive grant (FY26 STI) and under the Nanosonics Equity Plan To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That
Slide 36: Resolution 6: Issue of Performance Rights to the CEO
Resolution 6 Issue of 625,363 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s FY27 Long- Term Incentive grant (FY27 LTI) and under the Nanosonics Equity Plan To consider and, if thought fit, to pass the following resolution as an ordinar
Slide 37: Resolution 7: Approval of the Nanosonics Equity Plan
Resolution 7 Approval of the Nanosonics Equity Plan To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purpose of ASX Listing Rule 7.2 (Exception 13) and for all other purposes, the Nanosonics Equity Plan (the terms and conditions of which are s
Slide 38: Increase in maximum aggregate Non-Executive Directors' Remuneration
Increase in maximum aggregate Non- Executive Directors’ Remuneration To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purposes of clauses 22.1 and 22.8 of the Company’s Constitution and ASX Listing Rule 10.17 (and for all other purposes), the
Slide 39: How to ask a question
How to ask a question • To ask a wri en question, select the Q & A icon. • Select the topic your question relates to from the drop-down list. • Type your question in the text box and press the send icon. • To ask a verbal question follow the instructions below the broadcast window. 39
Slide 40: How to vote
How to vote • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed 40
Slide 41: How to ask a question
How to ask a question • To ask a wri en question, select the Q & A icon. • Select the topic your question relates to from the drop-down list. • Type your question in the text box and press the send icon. • To ask a verbal question follow the instructions below the broadcast window. 41
Slide 42: Thank you
Thank you Nanosonics Limited 7-11 Talavera Road Macquarie Park, NSW 2113 Australia T +61 2 8063 1600 E [email protected] www.nanosonics.com.au ABN 11 095 076 896
Slide 43: Disclaimer
Disclaimer This presentation is intended to provide a general The information does not constitute advice of any Subject to any continuing obligations under outline only and is not intended to be a definitive kind and should not be relied on as such. Investors applicable law or any relevant listing ru